Note: All changes are versus the prior-year period unless otherwise stated
"We have succeeded in mobilising for accelerated, efficient growth in all business sectors. Especially our Big 3, our healthcare pipeline, process solutions and semiconductor solutions, contributed to [our] excellent Q2 performance," commented Merck KGaA chief executive Belén Garijo.
Merck now expects sales this year of between €18.8 billion ($22.3 billion) and €19.7 billion ($23.3 billion), boosted from a prior estimated range of €18.5 billion ($21.9 billion) to €19.5 billion ($23.1 billion), mainly driven by Mavenclad, Bavencio and the recovery of its fertility products. Meanwhile, earnings per share are forecast to be between €7.80 ($9.23) and €8.50 ($10.06), lifted from a previous prediction of €7.50 ($8.88) to €8.20 ($9.71).
With regards to the coronavirus pandemic, the company said it "does not expect that further disease waves will have a negative effect comparable to that seen in the first half of 2020, especially on the healthcare…business."
However, for 2022, Merck indicated that new products from its development pipeline will only lift sales in its healthcare unit by between €1.6 billion ($1.9 billion) and €1.8 billion ($2.1 billion), down from a previous estimate of around €2 billion ($2.4 billion). The company explained that while it still expects peak Mavenclad sales of between €1 billion ($1.2 billion) and €1.4 billion ($1.7 billion), hitting this goal will occur at a later date due to the COVID-19 pandemic. Meanwhile, Merck said it expects "significant pandemic-related sales" in 2022 for the Life Science business.
To read more Top Story articles, click here.